Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

Purpose: To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC). Methods: We studied progression-free survival (PFS) in 91 ACC...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 101; no. 2; pp. 357 - 362
Main Authors Kweekel, D M, Antonini, N F, Nortier, J W R, Punt, C J A, Gelderblom, H, Guchelaar, H-J
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 21.07.2009
Nature Publishing Group
Subjects
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacology
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Ataxia Telangiectasia Mutated Proteins
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Cancer Research
Cancer therapies
Capecitabine
Cell Cycle Proteins - genetics
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Cyclin-dependent kinases
Deoxycytidine - administration & dosage
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Disease-Free Survival
DNA repair
DNA Repair - genetics
DNA, Neoplasm - blood
DNA, Neoplasm - genetics
DNA-Binding Proteins - genetics
Drug dosages
Drug Resistance
Endonucleases - genetics
Epidemiology
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Fluorouracil - analogs & derivatives
Genes
Genetics and Genomics
Genomes
Hematology
Humans
Kinases
Medical research
Medical sciences
Molecular Medicine
Neurotoxicity
Nuclear Proteins - genetics
Oncology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
Organoplatinum Compounds - pharmacology
Polymorphism, Single Nucleotide
Protein-Serine-Threonine Kinases - genetics
Toxicity
Transcription Factors - genetics
Tumor Suppressor Proteins - genetics
Tumors
Netherlands
toxicity
oxaliplatin
SNP array
efficacy
Antineoplastic agent
Toxicity
Treatment efficiency
ERCC5 gene
DNA repair
Repair gene
Alkylating agent
Cancerology
Oxaliplatin
DNA
Candidate gene
ATM
ERCC5
Platinum II Complexes
Tumor suppressor gene
Online AccessGet full text

Cover

Abstract Purpose: To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC). Methods: We studied progression-free survival (PFS) in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an Asper Biotech array. Overall survival (OS) and toxicity were studied as secondary end points. A step-wise selection of SNPs was performed, involving univariate and multivariate log-rank tests and Cox regression analysis, with age and performance status as covariates. Results: A total of 81 SNPs in 46 genes on the array were selected for further analysis, based on genotyping success rates and minor allele frequencies. After step-wise selection, we found that homozygosity for the ataxia telangiectasia mutated gene ( ATM ) rs1801516 or excision repair cross-complementing gene ( ERCC5 ) rs1047768 SNPs was associated with shorter PFS; however there were no significant associations ( P >0.01) with OS or toxicity. Discussion: This is the first study describing the pathway gene approach for the selection of new candidate genes involved in oxaliplatin efficacy and toxicity. The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.
AbstractList To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC). We studied progression-free survival (PFS) in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an Asper Biotech array. Overall survival (OS) and toxicity were studied as secondary end points. A step-wise selection of SNPs was performed, involving univariate and multivariate log-rank tests and Cox regression analysis, with age and performance status as covariates. A total of 81 SNPs in 46 genes on the array were selected for further analysis, based on genotyping success rates and minor allele frequencies. After step-wise selection, we found that homozygosity for the ataxia telangiectasia mutated gene (ATM) rs1801516 or excision repair cross-complementing gene (ERCC5) rs1047768 SNPs was associated with shorter PFS; however there were no significant associations (P>0.01) with OS or toxicity. This is the first study describing the pathway gene approach for the selection of new candidate genes involved in oxaliplatin efficacy and toxicity. The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.
To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC). We studied progression-free survival (PFS) in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an Asper Biotech array. Overall survival (OS) and toxicity were studied as secondary end points. A step-wise selection of SNPs was performed, involving univariate and multivariate log-rank tests and Cox regression analysis, with age and performance status as covariates. A total of 81 SNPs in 46 genes on the array were selected for further analysis, based on genotyping success rates and minor allele frequencies. After step-wise selection, we found that homozygosity for the ataxia telangiectasia mutated gene (ATM) rs1801516 or excision repair cross-complementing gene (ERCC5) rs1047768 SNPs was associated with shorter PFS; however there were no significant associations (P>0.01) with OS or toxicity. This is the first study describing the pathway gene approach for the selection of new candidate genes involved in oxaliplatin efficacy and toxicity. The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.
Purpose:To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC). Methods:We studied progression-free survival (PFS) in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an Asper Biotech array. Overall survival (OS) and toxicity were studied as secondary end points. A step-wise selection of SNPs was performed, involving univariate and multivariate log-rank tests and Cox regression analysis, with age and performance status as covariates. Results:A total of 81 SNPs in 46 genes on the array were selected for further analysis, based on genotyping success rates and minor allele frequencies. After step-wise selection, we found that homozygosity for the ataxia telangiectasia mutated gene (ATM) rs1801516 or excision repair cross-complementing gene (ERCC5) rs1047768 SNPs was associated with shorter PFS; however there were no significant associations (P>0.01) with OS or toxicity.Discussion:This is the first study describing the pathway gene approach for the selection of new candidate genes involved in oxaliplatin efficacy and toxicity. The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.British Journal of Cancer (2009) 101, 357-362; doi:10.1038/sj.bjc.6605134 www.bjcancer.com Published online 16 June 2009
Purpose: To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC). Methods: We studied progression-free survival (PFS) in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an Asper Biotech array. Overall survival (OS) and toxicity were studied as secondary end points. A step-wise selection of SNPs was performed, involving univariate and multivariate log-rank tests and Cox regression analysis, with age and performance status as covariates. Results: A total of 81 SNPs in 46 genes on the array were selected for further analysis, based on genotyping success rates and minor allele frequencies. After step-wise selection, we found that homozygosity for the ataxia telangiectasia mutated gene ( ATM ) rs1801516 or excision repair cross-complementing gene ( ERCC5 ) rs1047768 SNPs was associated with shorter PFS; however there were no significant associations ( P >0.01) with OS or toxicity. Discussion: This is the first study describing the pathway gene approach for the selection of new candidate genes involved in oxaliplatin efficacy and toxicity. The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.
Author Nortier, J W R
Kweekel, D M
Antonini, N F
Guchelaar, H-J
Punt, C J A
Gelderblom, H
Author_xml – sequence: 1
  givenname: D M
  surname: Kweekel
  fullname: Kweekel, D M
  email: d.m.kweekel@lumc.nl
  organization: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center
– sequence: 2
  givenname: N F
  surname: Antonini
  fullname: Antonini, N F
  organization: Biometrics Department, Netherlands Cancer Institute (NKI)
– sequence: 3
  givenname: J W R
  surname: Nortier
  fullname: Nortier, J W R
  organization: Department of Clinical Oncology, Leiden University Medical Center
– sequence: 4
  givenname: C J A
  surname: Punt
  fullname: Punt, C J A
  organization: Department of Oncology, Radboud University Nijmegen Medical Center
– sequence: 5
  givenname: H
  surname: Gelderblom
  fullname: Gelderblom, H
  organization: Department of Clinical Oncology, Leiden University Medical Center
– sequence: 6
  givenname: H-J
  surname: Guchelaar
  fullname: Guchelaar, H-J
  organization: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21938223$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19536092$$D View this record in MEDLINE/PubMed
BookMark eNp1kUuP0zAUhS00iOkUtuxAFhLs2nHsJnY2I42G4SGNYANr68a-Ka5Su9hJ1fx7XDV0AImVfXW--zxX5MIHj4S8LNiyYEJdp82y2ZhlVbGyEKsnZFaUgi8KxeUFmTHG5ILVnF2Sq5Q2OayZks_IZVGXosrCjIz3h10XIvRujzT1gx1pH6iz6HvXjtSHPXbUgLfOQo90jR4TjdjlwB7JcIDO7XLoPMW2dQbMSDOetYMzrh_pkJxfU6Dvv9zmxB24SCFGGJ-Tpy10CV9M75x8_3D_7e7T4uHrx893tw8LUwrVL0pjQfBa1o0sAZVo61Y0WGErQWHRVI2yplrZlVEs_4S1pkRpJF8ZgYyrWszJzanubmi2aE3eLEKnd9FtIY46gNN_K9790Ouw11xyxvM55-TdVCCGnwOmXm9dMth14DEMSXMmq6qUKoNv_gE3YYg-L6e5OB5f8SO0PEEmhpQitudJCqaPluq00dlSPVmaE17_Of8jPnmYgbcTAMlA10bwxqUzx4taKM5F5q5PXMqSX2N8HO-_rV-dMjz0Q8Rzyd_6LyYfySc
CODEN BJCAAI
CitedBy_id crossref_primary_10_1016_j_drup_2015_05_003
crossref_primary_10_1136_amiajnl_2012_001168
crossref_primary_10_1371_journal_pone_0048350
crossref_primary_10_1093_annonc_mdt546
crossref_primary_10_1038_s41467_018_05428_6
crossref_primary_10_1371_journal_pone_0061469
crossref_primary_10_1016_j_critrevonc_2023_104058
crossref_primary_10_3389_fphar_2020_577968
crossref_primary_10_1016_j_yexmp_2019_104364
crossref_primary_10_1111_cge_12710
crossref_primary_10_1016_j_ijrobp_2015_05_002
crossref_primary_10_1038_tpj_2012_26
crossref_primary_10_4238_2013_April_17_4
crossref_primary_10_1002_jcp_25966
crossref_primary_10_1186_s12967_016_0903_z
crossref_primary_10_1007_s00280_018_3629_1
crossref_primary_10_18632_aging_103094
crossref_primary_10_1080_09553002_2020_1711460
crossref_primary_10_3390_cancers15204972
crossref_primary_10_4137_BIC_S19681
crossref_primary_10_3748_wjg_v20_i29_9775
crossref_primary_10_3390_ijms22094432
crossref_primary_10_2217_pgs_13_237
crossref_primary_10_1038_sj_bjc_6605709
crossref_primary_10_1093_carcin_bgr071
crossref_primary_10_1016_j_dnarep_2018_07_005
crossref_primary_10_18632_oncotarget_18981
crossref_primary_10_2217_pgs_2015_0017
Cites_doi 10.1016/S0140-6736(03)12715-8
10.1158/1078-0432.CCR-04-2216
10.1158/1078-0432.CCR-07-1520
10.1038/sj.bjc.6601975
10.1016/j.ctrv.2004.12.006
10.1159/000113534
10.1016/j.tibtech.2005.05.011
10.1002/cncr.21885
10.1158/1078-0432.CCR-06-2543
10.1093/jnci/92.3.205
10.1158/1078-0432.CCR-04-0247
10.1016/j.ygyno.2007.07.024
10.2217/14622416.8.12.1693
10.1200/JCO.2006.08.1844
10.2353/jmoldx.2006.060018
10.1056/NEJMoa0804385
10.1074/jbc.M602826200
10.1093/annonc/mdh383
10.1093/annonc/mdl179
10.1038/sj.bjc.6604461
10.1200/JCO.2001.19.21.4097
10.2217/14622416.8.8.1075
10.1086/522374
10.1016/S0140-6736(07)61086-1
10.1200/JCO.2005.04.4206
10.1158/1078-0432.CCR-04-1953
10.1007/s00432-008-0355-9
10.1200/JCO.2004.08.067
10.1016/j.lungcan.2006.12.002
ContentType Journal Article
Copyright The Author(s) 2009
2009 INIST-CNRS
Copyright Nature Publishing Group Jul 21, 2009
Copyright © 2009 Cancer Research UK 2009 Cancer Research UK
Copyright_xml – notice: The Author(s) 2009
– notice: 2009 INIST-CNRS
– notice: Copyright Nature Publishing Group Jul 21, 2009
– notice: Copyright © 2009 Cancer Research UK 2009 Cancer Research UK
DBID C6C
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7RV
7TO
7U9
7X7
7XB
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
PQEST
PQQKQ
PQUKI
7TM
7U7
8FD
C1K
FR3
P64
RC3
5PM
DOI 10.1038/sj.bjc.6605134
DatabaseName SpringerOpen
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Nursing and Allied Health Journals
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection (ProQuest Medical & Health Databases)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (ProQuest Medical & Health Databases)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
British Nursing Database
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biological Science Database
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
Nucleic Acids Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Central (Alumni)
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
Nucleic Acids Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList MEDLINE
ProQuest Central Student
Genetics Abstracts
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Selection of new SNPs related to oxaliplatin efficacy
EISSN 1532-1827
EndPage 362
ExternalDocumentID 1787592561
10_1038_sj_bjc_6605134
19536092
21938223
6605134
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Netherlands
GeographicLocations_xml – name: Netherlands
GroupedDBID -
-Q-
02
0R
23N
39C
3V.
4.4
53G
5GY
5RE
70F
7RV
7X7
88E
8AO
8C1
8FI
8FJ
8R4
8R5
AADWK
AAPBV
AAWBL
AAWTL
AAYJO
AAZLF
ABAWZ
ABDBF
ABDEU
ABFLS
ABGIJ
ABOCM
ABPTK
ABUWG
ACGFS
ACKTT
ACPRK
ADACO
ADBBV
ADHDB
ADQMX
AEDAW
AEJRE
AENEX
AFKRA
AFRAH
AFSHS
AGEZK
AHMBA
AHSBF
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AN0
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BAWUL
BBAFP
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BNQBC
BPHCQ
BVXVI
CAG
COF
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EPL
ESX
EX3
F5P
FDQFY
FEDTE
FERAY
FIZPM
FRJ
FSGXE
FYUFA
GX1
HCIFZ
HVGLF
HYE
HZ
IH2
JSO
KQ8
M1P
M7P
NAO
NAPCQ
O9-
OK1
P2P
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
Q-
Q2X
RIG
RNT
RNTTT
RPM
SNX
SNYQT
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TR2
TUS
W2D
WH7
WOW
XFK
ZA5
---
0R~
36B
406
6J9
AANZL
ABAKF
ABLJU
ABZZP
ACAOD
ACGFO
ACRQY
ACZOJ
ADFRT
AEFQL
AEMSY
AEVLU
AFBBN
AGAYW
AGHAI
AGQEE
AILAN
AMYLF
AOIJS
C6C
CCPQU
DNIVK
DPUIP
EMOBN
HMCUK
HZ~
IWAJR
JZLTJ
NQJWS
SOHCF
SRMVM
UKHRP
~02
~8M
.55
.GJ
08R
8WZ
A6W
AATNV
AAUGY
AAYFA
ACBMV
ACBRV
ACBYP
ACIGE
ACTTH
ACVWB
ADMDM
ADYYL
AEFTE
AEXYK
AFNRJ
AGGBP
AI.
AJCLW
AJDOV
AMRJV
IQODW
J5H
M41
NYICJ
UDS
VH1
X7M
Y6R
ZGI
AAYZH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
7U9
7XB
8FE
8FH
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
LK8
7TM
7U7
8FD
C1K
FR3
P64
RC3
5PM
ID FETCH-LOGICAL-c538t-5cda32979b75ae83f9f3be6ef7a8e1b6b8dc64d4c808dc3ddc5e7c724c3e02893
IEDL.DBID RPM
ISSN 0007-0920
IngestDate Tue Sep 17 20:56:31 EDT 2024
Fri Oct 25 06:59:55 EDT 2024
Thu Oct 10 22:16:19 EDT 2024
Thu Sep 26 19:54:20 EDT 2024
Tue Oct 15 23:36:45 EDT 2024
Sun Oct 22 16:07:21 EDT 2023
Fri Oct 11 20:44:44 EDT 2024
Thu Oct 07 19:34:23 EDT 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords toxicity
oxaliplatin
SNP array
efficacy
Antineoplastic agent
Toxicity
Treatment efficiency
ERCC5 gene
DNA repair
Repair gene
Alkylating agent
Cancerology
Oxaliplatin
DNA
Candidate gene
ATM
ERCC5
Platinum II Complexes
Tumor suppressor gene
Language English
License CC BY 4.0
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c538t-5cda32979b75ae83f9f3be6ef7a8e1b6b8dc64d4c808dc3ddc5e7c724c3e02893
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720215/
PMID 19536092
PQID 230009828
PQPubID 41855
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2720215
proquest_miscellaneous_20766578
proquest_journals_230009828
crossref_primary_10_1038_sj_bjc_6605134
pubmed_primary_19536092
pascalfrancis_primary_21938223
springer_journals_10_1038_sj_bjc_6605134
nature_primary_6605134
ProviderPackageCode ABDEU
AEDAW
AAZLF
-Q-
AADWK
AAYJO
70F
ADQMX
EE.
RNTTT
SWTZT
ABGIJ
RNT
NAO
PublicationCentury 2000
PublicationDate 7-21-2009
PublicationDateYYYYMMDD 2009-07-21
PublicationDate_xml – month: 07
  year: 2009
  text: 7-21-2009
  day: 21
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: Basingstoke
– name: England
PublicationTitle British journal of cancer
PublicationTitleAbbrev Br J Cancer
PublicationTitleAlternate Br J Cancer
PublicationYear 2009
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Schrauder, M, Frank, S, Strissel, PL, Lux, MP, Bani, MR, Rauh, C, Sieber, CC, Heusinger, K, Hartmann, A, Schulz-Wendtland, R, Strick, R, Beckmann, MW, Fasching, PA 2008; 134
Li, D, Frazier, M, Evans, DB, Hess, KR, Crane, CH, Jiao, L, Abbruzzese, JL 2006; 24
Curtis, RK, Oresic, M, Vidal-Puig, A 2005; 23
Komar, AA 2007; 8
Le Morvan, V, Smith, D, Laurand, A, Brouste, V, Bellott, R, Soubeyran, I, Mathoulin-Pelissier, S, Robert, J 2007; 8
Giachino, DF, Ghio, P, Regazzoni, S, Mandrile, G, Novello, S, Selvaggi, G, Gregori, D, DeMarchi, M, Scagliotti, GV 2007; 13
Su, D, Ma, S, Liu, P, Jiang, Z, Lv, W, Zhang, Y, Deng, Q, Smith, S, Yu, H 2007; 56
Viguier, J, Boige, V, Miquel, C, Pocard, M, Giraudeau, B, Sabourin, JC, Ducreux, M, Sarasin, A, Praz, F 2005; 11
Park, DJ, Stoehlmacher, J, Zhang, W, Tsao-Wei, DD, Groshen, S, Lenz, HJ 2001; 61
Park, DJ, Zhang, W, Stoehlmacher, J, Tsao-Wei, D, Groshen, S, Gil, J, Yun, J, Sones, E, Mallik, N, Lenz, HJ 2003; 1
Wang, K, Li, M, Bucan, M 2007; 81
Zhou, W, Gurubhagavatula, S, Liu, G, Park, S, Neuberg, DS, Wain, JC, Lynch, TJ, Su, L, Christiani, DC 2004; 10
Stoehlmacher, J, Park, DJ, Zhang, W, Yang, D, Groshen, S, Zahedy, S, Lenz, HJ 2004; 91
Colhoun, HM, McKeigue, PM, Davey, SG 2003; 361
Kweekel, DM, Gelderblom, H, Guchelaar, HJ 2005; 31
Colton, SL, Xu, XS, Wang, YA, Wang, G 2006; 281
Monzo, M, Moreno, I, Navarro, A, Ibeas, R, Artells, R, Gel, B, Martinez, F, Moreno, J, Hernandez, R, Navarro-Vigo, M 2007; 72
Suk, R, Gurubhagavatula, S, Park, S, Zhou, W, Su, L, Lynch, TJ, Wain, JC, Neuberg, D, Liu, G, Christiani, DC 2005; 11
Van der Straaten, T, Kweekel, D, Tiller, M, Bogaartz, J, Guchelaar, HJ 2006; 8
Ruzzo, A, Graziano, F, Loupakis, F, Rulli, E, Canestrari, E, Santini, D, Catalano, V, Ficarelli, R, Maltese, P, Bisonni, R, Masi, G, Schiavon, G, Giordani, P, Giustini, L, Falcone, A, Tonini, G, Silva, R, Mattioli, R, Floriani, I, Magnani, M 2007; 25
Saldivar, JS, Lu, KH, Liang, D, Gu, J, Huang, M, Vlastos, AT, Follen, M, Wu, X 2007; 107
Booton, R, Ward, T, Heighway, J, Taylor, P, Power, F, Ashcroft, L, Morris, J, Thatcher, N 2006; 106
Kweekel, DM, Gelderblom, H, Van der Straaten, T, Antonini, NF, Punt, CJ, Guchelaar, HJ 2008; 99
Okazaki, T, Jiao, L, Chang, P, Evans, DB, Abbruzzese, JL, Li, D 2008; 14
Gurubhagavatula, S, Liu, G, Park, S, Zhou, W, Su, L, Wain, JC, Lynch, TJ, Neuberg, DS, Christiani, DC 2004; 22
Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L, Verweij, J, Van, GM, van Oosterom, AT, Christian, MC, Gwyther, SG 2000; 92
Punt, CJ 2004; 15
Koopman, M, Antonini, NF, Douma, J, Wals, J, Honkoop, AH, Erdkamp, FL, de Jong, RS, Rodenburg, CJ, Vreugdenhil, G, Loosveld, OJ, van, BA, Sinnige, HA, Creemers, GJ, Tesselaar, ME, Slee, PH, Werter, MJ, Mol, L, Dalesio, O, Punt, CJ 2007; 370
Van Cutsem, E, Twelves, C, Cassidy, J, Allman, D, Bajetta, E, Boyer, M, Bugat, R, Findlay, M, Frings, S, Jahn, M, McKendrick, J, Osterwalder, B, Perez-Manga, G, Rosso, R, Rougier, P, Schmiegel, WH, Seitz, JF, Thompson, P, Vieitez, JM, Weitzel, C, Harper, P 2001; 19
Karapetis, CS, Khambata-Ford, S, Jonker, DJ, O'Callaghan, CJ, Tu, D, Tebbutt, NC, Simes, RJ, Chalchal, H, Shapiro, JD, Robitaille, S, Price, TJ, Shepherd, L, Au, HJ, Langer, C, Moore, MJ, Zalcberg, JR 2008; 359
Koopman, M, Antonini, NF, Douma, J, Wals, J, Honkoop, AH, Erdkamp, FL, de Jong, RS, Rodenburg, CJ, Vreugdenhil, G, Akkermans-Vogelaar, JM, Punt, CJ 2006; 17
Karapetis, Khambata-Ford, Jonker, O'Callaghan, Tu, Tebbutt, Simes, Chalchal, Shapiro, Robitaille, Price, Shepherd, Au, Langer, Moore, Zalcberg (CR7) 2008; 359
Saldivar, Lu, Liang, Gu, Huang, Vlastos, Follen, Wu (CR21) 2007; 107
Giachino, Ghio, Regazzoni, Mandrile, Novello, Selvaggi, Gregori, DeMarchi, Scagliotti (CR5) 2007; 13
Gurubhagavatula, Liu, Park, Zhou, Su, Wain, Lynch, Neuberg, Christiani (CR6) 2004; 22
Stoehlmacher, Park, Zhang, Yang, Groshen, Zahedy, Lenz (CR23) 2004; 91
Ruzzo, Graziano, Loupakis, Rulli, Canestrari, Santini, Catalano, Ficarelli, Maltese, Bisonni, Masi, Schiavon, Giordani, Giustini, Falcone, Tonini, Silva, Mattioli, Floriani, Magnani (CR20) 2007; 25
Van der Straaten, Kweekel, Tiller, Bogaartz, Guchelaar (CR28) 2006; 8
Suk, Gurubhagavatula, Park, Zhou, Su, Lynch, Wain, Neuberg, Liu, Christiani (CR25) 2005; 11
Kweekel, Gelderblom, Guchelaar (CR11) 2005; 31
Li, Frazier, Evans, Hess, Crane, Jiao, Abbruzzese (CR14) 2006; 24
Koopman, Antonini, Douma, Wals, Honkoop, Erdkamp, de Jong, Rodenburg, Vreugdenhil, Akkermans-Vogelaar, Punt (CR9) 2006; 17
Therasse, Arbuck, Eisenhauer, Wanders, Kaplan, Rubinstein, Verweij, Van, van Oosterom, Christian, Gwyther (CR26) 2000; 92
Colton, Xu, Wang, Wang (CR3) 2006; 281
Monzo, Moreno, Navarro, Ibeas, Artells, Gel, Martinez, Moreno, Hernandez, Navarro-Vigo (CR15) 2007; 72
Colhoun, McKeigue, Davey (CR2) 2003; 361
Van Cutsem, Twelves, Cassidy, Allman, Bajetta, Boyer, Bugat, Findlay, Frings, Jahn, McKendrick, Osterwalder, Perez-Manga, Rosso, Rougier, Schmiegel, Seitz, Thompson, Vieitez, Weitzel, Harper (CR27) 2001; 19
Schrauder, Frank, Strissel, Lux, Bani, Rauh, Sieber, Heusinger, Hartmann, Schulz-Wendtland, Strick, Beckmann, Fasching (CR22) 2008; 134
Le Morvan, Smith, Laurand, Brouste, Bellott, Soubeyran, Mathoulin-Pelissier, Robert (CR13) 2007; 8
Komar (CR8) 2007; 8
Wang, Li, Bucan (CR30) 2007; 81
Punt (CR19) 2004; 15
Kweekel, Gelderblom, Van der Straaten, Antonini, Punt, Guchelaar (CR12) 2008; 99
Zhou, Gurubhagavatula, Liu, Park, Neuberg, Wain, Lynch, Su, Christiani (CR31) 2004; 10
Viguier, Boige, Miquel, Pocard, Giraudeau, Sabourin, Ducreux, Sarasin, Praz (CR29) 2005; 11
Su, Ma, Liu, Jiang, Lv, Zhang, Deng, Smith, Yu (CR24) 2007; 56
Booton, Ward, Heighway, Taylor, Power, Ashcroft, Morris, Thatcher (CR1) 2006; 106
Koopman, Antonini, Douma, Wals, Honkoop, Erdkamp, de Jong, Rodenburg, Vreugdenhil, Loosveld, van, Sinnige, Creemers, Tesselaar, Slee, Werter, Mol, Dalesio, Punt (CR10) 2007; 370
Park, Stoehlmacher, Zhang, Tsao-Wei, Groshen, Lenz (CR17) 2001; 61
Curtis, Oresic, Vidal-Puig (CR4) 2005; 23
Okazaki, Jiao, Chang, Evans, Abbruzzese, Li (CR16) 2008; 14
Park, Zhang, Stoehlmacher, Tsao-Wei, Groshen, Gil, Yun, Sones, Mallik, Lenz (CR18) 2003; 1
12642066 - Lancet. 2003 Mar 8;361(9360):865-72
16849332 - J Biol Chem. 2006 Sep 15;281(37):27117-25
16520463 - J Clin Oncol. 2006 Apr 10;24(11):1720-8
18264724 - J Cancer Res Clin Oncol. 2008 Aug;134(8):873-82
11689577 - J Clin Oncol. 2001 Nov 1;19(21):4097-106
16224397 - Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6
18381943 - Clin Cancer Res. 2008 Apr 1;14(7):2042-8
15746057 - Clin Cancer Res. 2005 Feb 15;11(4):1534-8
20531418 - Br J Cancer. 2010 Jun 8;102(12):1791-2
18946061 - N Engl J Med. 2008 Oct 23;359(17):1757-65
10655437 - J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
15173214 - J Clin Oncol. 2004 Jul 1;22(13):2594-601
15847979 - Cancer Treat Rev. 2005 Apr;31(2):90-105
15950303 - Trends Biotechnol. 2005 Aug;23(8):429-35
16144923 - Clin Cancer Res. 2005 Sep 1;11(17):6212-7
17504986 - Clin Cancer Res. 2007 May 15;13(10):2876-81
16873425 - Ann Oncol. 2006 Oct;17(10):1523-8
16649224 - Cancer. 2006 Jun 1;106(11):2421-7
17222938 - Lung Cancer. 2007 May;56(2):281-8
17630036 - Lancet. 2007 Jul 14;370(9582):135-42
17716239 - Pharmacogenomics. 2007 Aug;8(8):1075-80
17966091 - Am J Hum Genet. 2007 Dec;81(6):1278-83
15297394 - Clin Cancer Res. 2004 Aug 1;10(15):4939-43
15213713 - Br J Cancer. 2004 Jul 19;91(2):344-54
18204222 - Oncology. 2007;72(5-6):364-70
11751380 - Cancer Res. 2001 Dec 15;61(24):8654-8
17825393 - Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S223-9
18594531 - Br J Cancer. 2008 Jul 22;99(2):275-82
18085999 - Pharmacogenomics. 2007 Dec;8(12):1693-703
16931584 - J Mol Diagn. 2006 Sep;8(4):444-8
17401013 - J Clin Oncol. 2007 Apr 1;25(10):1247-54
15367403 - Ann Oncol. 2004 Oct;15(10):1453-9
D Su (BF6605134_CR24) 2007; 56
T Okazaki (BF6605134_CR16) 2008; 14
DM Kweekel (BF6605134_CR12) 2008; 99
HM Colhoun (BF6605134_CR2) 2003; 361
S Gurubhagavatula (BF6605134_CR6) 2004; 22
DF Giachino (BF6605134_CR5) 2007; 13
M Koopman (BF6605134_CR10) 2007; 370
DJ Park (BF6605134_CR17) 2001; 61
RK Curtis (BF6605134_CR4) 2005; 23
DM Kweekel (BF6605134_CR11) 2005; 31
M Schrauder (BF6605134_CR22) 2008; 134
J Viguier (BF6605134_CR29) 2005; 11
V Le Morvan (BF6605134_CR13) 2007; 8
CJ Punt (BF6605134_CR19) 2004; 15
SL Colton (BF6605134_CR3) 2006; 281
M Monzo (BF6605134_CR15) 2007; 72
D Li (BF6605134_CR14) 2006; 24
P Therasse (BF6605134_CR26) 2000; 92
K Wang (BF6605134_CR30) 2007; 81
JS Saldivar (BF6605134_CR21) 2007; 107
M Koopman (BF6605134_CR9) 2006; 17
T Van der Straaten (BF6605134_CR28) 2006; 8
CS Karapetis (BF6605134_CR7) 2008; 359
J Stoehlmacher (BF6605134_CR23) 2004; 91
R Suk (BF6605134_CR25) 2005; 11
AA Komar (BF6605134_CR8) 2007; 8
DJ Park (BF6605134_CR18) 2003; 1
E Van Cutsem (BF6605134_CR27) 2001; 19
A Ruzzo (BF6605134_CR20) 2007; 25
W Zhou (BF6605134_CR31) 2004; 10
R Booton (BF6605134_CR1) 2006; 106
References_xml – volume: 281
  start-page: 27117
  year: 2006
  end-page: 27125
  article-title: The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment
  publication-title: J Biol Chem
  contributor:
    fullname: Wang, G
– volume: 81
  start-page: 1278
  year: 2007
  end-page: 1283
  article-title: Pathway-based approaches for analysis of genomewide association studies
  publication-title: Am J Hum Genet
  contributor:
    fullname: Bucan, M
– volume: 106
  start-page: 2421
  year: 2006
  end-page: 2427
  article-title: Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer
  publication-title: Cancer
  contributor:
    fullname: Thatcher, N
– volume: 61
  start-page: 8654
  year: 2001
  end-page: 8658
  article-title: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer
  publication-title: Cancer Res
  contributor:
    fullname: Lenz, HJ
– volume: 11
  start-page: 1534
  year: 2005
  end-page: 1538
  article-title: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
  publication-title: Clin Cancer Res
  contributor:
    fullname: Christiani, DC
– volume: 24
  start-page: 1720
  year: 2006
  end-page: 1728
  article-title: Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer
  publication-title: J Clin Oncol
  contributor:
    fullname: Abbruzzese, JL
– volume: 11
  start-page: 6212
  year: 2005
  end-page: 6217
  article-title: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Praz, F
– volume: 99
  start-page: 275
  year: 2008
  end-page: 282
  article-title: UGT1A1 28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
  publication-title: Br J Cancer
  contributor:
    fullname: Guchelaar, HJ
– volume: 359
  start-page: 1757
  year: 2008
  end-page: 1765
  article-title: K-ras mutations and benefit from cetuximab in advanced colorectal cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Zalcberg, JR
– volume: 8
  start-page: 1075
  year: 2007
  end-page: 1080
  article-title: Silent SNPs: impact on gene function and phenotype
  publication-title: Pharmacogenomics
  contributor:
    fullname: Komar, AA
– volume: 72
  start-page: 364
  year: 2007
  end-page: 370
  article-title: Single nucleotide polymorphisms in nucleotide excision repair genes , , and in advanced colorectal cancer patients treated with first-line oxaliplatin fluoropyrimidine
  publication-title: Oncology
  contributor:
    fullname: Navarro-Vigo, M
– volume: 134
  start-page: 873
  year: 2008
  end-page: 882
  article-title: Single nucleotide polymorphism D1853N of the gene may alter the risk for breast cancer
  publication-title: J Cancer Res Clin Oncol
  contributor:
    fullname: Fasching, PA
– volume: 17
  start-page: 1523
  year: 2006
  end-page: 1528
  article-title: Randomised study of sequential combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
  publication-title: Ann Oncol
  contributor:
    fullname: Punt, CJ
– volume: 31
  start-page: 90
  year: 2005
  end-page: 105
  article-title: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
  publication-title: Cancer Treat Rev
  contributor:
    fullname: Guchelaar, HJ
– volume: 19
  start-page: 4097
  year: 2001
  end-page: 4106
  article-title: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study
  publication-title: J Clin Oncol
  contributor:
    fullname: Harper, P
– volume: 8
  start-page: 444
  year: 2006
  end-page: 448
  article-title: Multiplex pyrosequencing of two polymorphisms in DNA repair gene
  publication-title: J Mol Diagn
  contributor:
    fullname: Guchelaar, HJ
– volume: 8
  start-page: 1693
  year: 2007
  end-page: 1703
  article-title: Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome
  publication-title: Pharmacogenomics
  contributor:
    fullname: Robert, J
– volume: 13
  start-page: 2876
  year: 2007
  end-page: 2881
  article-title: Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Scagliotti, GV
– volume: 92
  start-page: 205
  year: 2000
  end-page: 216
  article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
  publication-title: J Natl Cancer Inst
  contributor:
    fullname: Gwyther, SG
– volume: 25
  start-page: 1247
  year: 2007
  end-page: 1254
  article-title: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
  publication-title: J Clin Oncol
  contributor:
    fullname: Magnani, M
– volume: 370
  start-page: 135
  year: 2007
  end-page: 142
  article-title: Sequential combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
  publication-title: Lancet
  contributor:
    fullname: Punt, CJ
– volume: 361
  start-page: 865
  year: 2003
  end-page: 872
  article-title: Problems of reporting genetic associations with complex outcomes
  publication-title: Lancet
  contributor:
    fullname: Davey, SG
– volume: 22
  start-page: 2594
  year: 2004
  end-page: 2601
  article-title: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
  publication-title: J Clin Oncol
  contributor:
    fullname: Christiani, DC
– volume: 91
  start-page: 344
  year: 2004
  end-page: 354
  article-title: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU oxaliplatin combination chemotherapy in refractory colorectal cancer
  publication-title: Br J Cancer
  contributor:
    fullname: Lenz, HJ
– volume: 14
  start-page: 2042
  year: 2008
  end-page: 2048
  article-title: Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Li, D
– volume: 107
  start-page: S223
  year: 2007
  end-page: S229
  article-title: Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
  publication-title: Gynecol Oncol
  contributor:
    fullname: Wu, X
– volume: 1
  start-page: 162
  year: 2003
  end-page: 166
  article-title: gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Lenz, HJ
– volume: 15
  start-page: 1453
  year: 2004
  end-page: 1459
  article-title: New options and old dilemmas in the treatment of patients with advanced colorectal cancer
  publication-title: Ann Oncol
  contributor:
    fullname: Punt, CJ
– volume: 23
  start-page: 429
  year: 2005
  end-page: 435
  article-title: Pathways to the analysis of microarray data
  publication-title: Trends Biotechnol
  contributor:
    fullname: Vidal-Puig, A
– volume: 56
  start-page: 281
  year: 2007
  end-page: 288
  article-title: Genetic polymorphisms and treatment response in advanced non-small cell lung cancer
  publication-title: Lung Cancer
  contributor:
    fullname: Yu, H
– volume: 10
  start-page: 4939
  year: 2004
  end-page: 4943
  article-title: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Christiani, DC
– volume: 361
  start-page: 865
  year: 2003
  end-page: 872
  ident: CR2
  article-title: Problems of reporting genetic associations with complex outcomes
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)12715-8
  contributor:
    fullname: Davey
– volume: 11
  start-page: 6212
  year: 2005
  end-page: 6217
  ident: CR29
  article-title: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-2216
  contributor:
    fullname: Praz
– volume: 14
  start-page: 2042
  year: 2008
  end-page: 2048
  ident: CR16
  article-title: Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1520
  contributor:
    fullname: Li
– volume: 91
  start-page: 344
  year: 2004
  end-page: 354
  ident: CR23
  article-title: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601975
  contributor:
    fullname: Lenz
– volume: 31
  start-page: 90
  year: 2005
  end-page: 105
  ident: CR11
  article-title: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2004.12.006
  contributor:
    fullname: Guchelaar
– volume: 72
  start-page: 364
  year: 2007
  end-page: 370
  ident: CR15
  article-title: Single nucleotide polymorphisms in nucleotide excision repair genes , , and in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine
  publication-title: Oncology
  doi: 10.1159/000113534
  contributor:
    fullname: Navarro-Vigo
– volume: 23
  start-page: 429
  year: 2005
  end-page: 435
  ident: CR4
  article-title: Pathways to the analysis of microarray data
  publication-title: Trends Biotechnol
  doi: 10.1016/j.tibtech.2005.05.011
  contributor:
    fullname: Vidal-Puig
– volume: 106
  start-page: 2421
  year: 2006
  end-page: 2427
  ident: CR1
  article-title: Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer
  publication-title: Cancer
  doi: 10.1002/cncr.21885
  contributor:
    fullname: Thatcher
– volume: 13
  start-page: 2876
  year: 2007
  end-page: 2881
  ident: CR5
  article-title: Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2543
  contributor:
    fullname: Scagliotti
– volume: 92
  start-page: 205
  year: 2000
  end-page: 216
  ident: CR26
  article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.3.205
  contributor:
    fullname: Gwyther
– volume: 10
  start-page: 4939
  year: 2004
  end-page: 4943
  ident: CR31
  article-title: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0247
  contributor:
    fullname: Christiani
– volume: 107
  start-page: S223
  year: 2007
  end-page: S229
  ident: CR21
  article-title: Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2007.07.024
  contributor:
    fullname: Wu
– volume: 8
  start-page: 1693
  year: 2007
  end-page: 1703
  ident: CR13
  article-title: Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.8.12.1693
  contributor:
    fullname: Robert
– volume: 61
  start-page: 8654
  year: 2001
  end-page: 8658
  ident: CR17
  article-title: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer
  publication-title: Cancer Res
  contributor:
    fullname: Lenz
– volume: 25
  start-page: 1247
  year: 2007
  end-page: 1254
  ident: CR20
  article-title: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.1844
  contributor:
    fullname: Magnani
– volume: 8
  start-page: 444
  year: 2006
  end-page: 448
  ident: CR28
  article-title: Multiplex pyrosequencing of two polymorphisms in DNA repair gene
  publication-title: J Mol Diagn
  doi: 10.2353/jmoldx.2006.060018
  contributor:
    fullname: Guchelaar
– volume: 359
  start-page: 1757
  year: 2008
  end-page: 1765
  ident: CR7
  article-title: K-ras mutations and benefit from cetuximab in advanced colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0804385
  contributor:
    fullname: Zalcberg
– volume: 1
  start-page: 162
  year: 2003
  end-page: 166
  ident: CR18
  article-title: gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Lenz
– volume: 281
  start-page: 27117
  year: 2006
  end-page: 27125
  ident: CR3
  article-title: The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M602826200
  contributor:
    fullname: Wang
– volume: 15
  start-page: 1453
  year: 2004
  end-page: 1459
  ident: CR19
  article-title: New options and old dilemmas in the treatment of patients with advanced colorectal cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdh383
  contributor:
    fullname: Punt
– volume: 17
  start-page: 1523
  year: 2006
  end-page: 1528
  ident: CR9
  article-title: Randomised study of sequential combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdl179
  contributor:
    fullname: Punt
– volume: 99
  start-page: 275
  year: 2008
  end-page: 282
  ident: CR12
  article-title: UGT1A1 28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604461
  contributor:
    fullname: Guchelaar
– volume: 19
  start-page: 4097
  year: 2001
  end-page: 4106
  ident: CR27
  article-title: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.21.4097
  contributor:
    fullname: Harper
– volume: 8
  start-page: 1075
  year: 2007
  end-page: 1080
  ident: CR8
  article-title: Silent SNPs: impact on gene function and phenotype
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.8.8.1075
  contributor:
    fullname: Komar
– volume: 81
  start-page: 1278
  year: 2007
  end-page: 1283
  ident: CR30
  article-title: Pathway-based approaches for analysis of genomewide association studies
  publication-title: Am J Hum Genet
  doi: 10.1086/522374
  contributor:
    fullname: Bucan
– volume: 370
  start-page: 135
  year: 2007
  end-page: 142
  ident: CR10
  article-title: Sequential combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)61086-1
  contributor:
    fullname: Punt
– volume: 24
  start-page: 1720
  year: 2006
  end-page: 1728
  ident: CR14
  article-title: Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.04.4206
  contributor:
    fullname: Abbruzzese
– volume: 11
  start-page: 1534
  year: 2005
  end-page: 1538
  ident: CR25
  article-title: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1953
  contributor:
    fullname: Christiani
– volume: 134
  start-page: 873
  year: 2008
  end-page: 882
  ident: CR22
  article-title: Single nucleotide polymorphism D1853N of the gene may alter the risk for breast cancer
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-008-0355-9
  contributor:
    fullname: Fasching
– volume: 22
  start-page: 2594
  year: 2004
  end-page: 2601
  ident: CR6
  article-title: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.08.067
  contributor:
    fullname: Christiani
– volume: 56
  start-page: 281
  year: 2007
  end-page: 288
  ident: CR24
  article-title: Genetic polymorphisms and treatment response in advanced non-small cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2006.12.002
  contributor:
    fullname: Yu
– volume: 15
  start-page: 1453
  year: 2004
  ident: BF6605134_CR19
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdh383
  contributor:
    fullname: CJ Punt
– volume: 281
  start-page: 27117
  year: 2006
  ident: BF6605134_CR3
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M602826200
  contributor:
    fullname: SL Colton
– volume: 14
  start-page: 2042
  year: 2008
  ident: BF6605134_CR16
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1520
  contributor:
    fullname: T Okazaki
– volume: 99
  start-page: 275
  year: 2008
  ident: BF6605134_CR12
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604461
  contributor:
    fullname: DM Kweekel
– volume: 56
  start-page: 281
  year: 2007
  ident: BF6605134_CR24
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2006.12.002
  contributor:
    fullname: D Su
– volume: 25
  start-page: 1247
  year: 2007
  ident: BF6605134_CR20
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.1844
  contributor:
    fullname: A Ruzzo
– volume: 22
  start-page: 2594
  year: 2004
  ident: BF6605134_CR6
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.08.067
  contributor:
    fullname: S Gurubhagavatula
– volume: 61
  start-page: 8654
  year: 2001
  ident: BF6605134_CR17
  publication-title: Cancer Res
  contributor:
    fullname: DJ Park
– volume: 17
  start-page: 1523
  year: 2006
  ident: BF6605134_CR9
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdl179
  contributor:
    fullname: M Koopman
– volume: 11
  start-page: 1534
  year: 2005
  ident: BF6605134_CR25
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1953
  contributor:
    fullname: R Suk
– volume: 19
  start-page: 4097
  year: 2001
  ident: BF6605134_CR27
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.21.4097
  contributor:
    fullname: E Van Cutsem
– volume: 107
  start-page: S223
  year: 2007
  ident: BF6605134_CR21
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2007.07.024
  contributor:
    fullname: JS Saldivar
– volume: 134
  start-page: 873
  year: 2008
  ident: BF6605134_CR22
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-008-0355-9
  contributor:
    fullname: M Schrauder
– volume: 359
  start-page: 1757
  year: 2008
  ident: BF6605134_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0804385
  contributor:
    fullname: CS Karapetis
– volume: 81
  start-page: 1278
  year: 2007
  ident: BF6605134_CR30
  publication-title: Am J Hum Genet
  doi: 10.1086/522374
  contributor:
    fullname: K Wang
– volume: 24
  start-page: 1720
  year: 2006
  ident: BF6605134_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.04.4206
  contributor:
    fullname: D Li
– volume: 10
  start-page: 4939
  year: 2004
  ident: BF6605134_CR31
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0247
  contributor:
    fullname: W Zhou
– volume: 72
  start-page: 364
  year: 2007
  ident: BF6605134_CR15
  publication-title: Oncology
  doi: 10.1159/000113534
  contributor:
    fullname: M Monzo
– volume: 1
  start-page: 162
  year: 2003
  ident: BF6605134_CR18
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: DJ Park
– volume: 106
  start-page: 2421
  year: 2006
  ident: BF6605134_CR1
  publication-title: Cancer
  doi: 10.1002/cncr.21885
  contributor:
    fullname: R Booton
– volume: 31
  start-page: 90
  year: 2005
  ident: BF6605134_CR11
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2004.12.006
  contributor:
    fullname: DM Kweekel
– volume: 23
  start-page: 429
  year: 2005
  ident: BF6605134_CR4
  publication-title: Trends Biotechnol
  doi: 10.1016/j.tibtech.2005.05.011
  contributor:
    fullname: RK Curtis
– volume: 370
  start-page: 135
  year: 2007
  ident: BF6605134_CR10
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)61086-1
  contributor:
    fullname: M Koopman
– volume: 8
  start-page: 1693
  year: 2007
  ident: BF6605134_CR13
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.8.12.1693
  contributor:
    fullname: V Le Morvan
– volume: 92
  start-page: 205
  year: 2000
  ident: BF6605134_CR26
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.3.205
  contributor:
    fullname: P Therasse
– volume: 8
  start-page: 1075
  year: 2007
  ident: BF6605134_CR8
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.8.8.1075
  contributor:
    fullname: AA Komar
– volume: 361
  start-page: 865
  year: 2003
  ident: BF6605134_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)12715-8
  contributor:
    fullname: HM Colhoun
– volume: 91
  start-page: 344
  year: 2004
  ident: BF6605134_CR23
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601975
  contributor:
    fullname: J Stoehlmacher
– volume: 13
  start-page: 2876
  year: 2007
  ident: BF6605134_CR5
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2543
  contributor:
    fullname: DF Giachino
– volume: 8
  start-page: 444
  year: 2006
  ident: BF6605134_CR28
  publication-title: J Mol Diagn
  doi: 10.2353/jmoldx.2006.060018
  contributor:
    fullname: T Van der Straaten
– volume: 11
  start-page: 6212
  year: 2005
  ident: BF6605134_CR29
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-2216
  contributor:
    fullname: J Viguier
SSID ssj0009087
Score 2.1602516
Snippet Purpose: To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in...
To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients...
Purpose:To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients...
SourceID pubmedcentral
proquest
crossref
pubmed
pascalfrancis
springer
nature
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 357
SubjectTerms Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacology
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Ataxia Telangiectasia Mutated Proteins
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Cancer Research
Cancer therapies
Capecitabine
Cell Cycle Proteins - genetics
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Cyclin-dependent kinases
Deoxycytidine - administration & dosage
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Disease-Free Survival
DNA repair
DNA Repair - genetics
DNA, Neoplasm - blood
DNA, Neoplasm - genetics
DNA-Binding Proteins - genetics
Drug dosages
Drug Resistance
Endonucleases - genetics
Epidemiology
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Fluorouracil - analogs & derivatives
Genes
Genetics and Genomics
Genomes
Hematology
Humans
Kinases
Medical research
Medical sciences
Molecular Medicine
Neurotoxicity
Nuclear Proteins - genetics
Oncology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
Organoplatinum Compounds - pharmacology
Polymorphism, Single Nucleotide
Protein-Serine-Threonine Kinases - genetics
Toxicity
Transcription Factors - genetics
Tumor Suppressor Proteins - genetics
Tumors
SummonAdditionalLinks – databaseName: Public Health Database (ProQuest Medical & Health Databases)
  dbid: 8C1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Na9wwEBVtCqUQSvqRxk2a6lBoL05sS7akUwlpQygkpwZyM7IspbsU21k7If73nZE_lm1DbwszxlrPaPTQGz0R8kmx2AqeFiEDNBxy5dJQKe7CVGXCFcrp2ItVX1xm51f8x3V6PfbmtGNb5VQTfaEua4N75McAlVH7MpFfm9sQL41CcnW8QeMpeRbDMocdffJ03eGhIjlIZuJunEqiSbORyeN2eVQszVEGYD5mfGNNmhU1txvdwndywwUXjyHQfxsp_2JT_SJ1tkNejuiSngzp8Io8sdVr8vxi5M_fkH5oufNi39Qry9Kupgt_WNf1tKrv7W9q8KQLbgTQGyyE1B93sSV61g8A2xtsn6uoRfEJbXoK7mB7gFd0PcU--huq6bfLE3iw0YsV1auV7t-Sq7PvP0_Pw_HyhdBADezC1JSaJUqoQqTaSuaUY4XNrBNa2rjIClmajJfcyAh-sbI0qRVGJNwwi-wl2yVbVV3ZPUJjZWGB1E4KB3hFp4Xi3LG4tGUMb4nSgHyePn_eDBobuefGmczbZQ6BysdABWR3iM7sNxsON6I126EgM8BALCD7U_jycZa2-ZxTAfk4W2F6IWeiK1vfgUskkJsCj3dDqNcjROIb0iogYiMJZgcU7t60VItfXsAbuW-AWgH5MqXLekyP__H3_x3-PnkxkFwiTOIDstWt7uwHwEpdcehnxB-N0RWv
  priority: 102
  providerName: ProQuest
– databaseName: SpringerOpen
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEB7aFEqhlL7SunlUh0J7cWpbkiUdwzYhFJJTA7kZWZbSXYq97Doh_vcZyV4vTnLozTAjJGv0-Oxv9Angm6KpFYyXMUU0HDPleKwUczFXuXClcjoNYtXnF_nZJft9xa-GBFl_FmbC31P5c704KhfmKEfUnVL2HF7g_it96tYsn23FdRPZa2P6324qSzbijI_KTzafUTrz9VKvsUNcf5PFU1DzccbkA9o07Eanb-HNACPJcR_3d_DM1u_h5flAlH-Ars-tC6reJEjIkrYh83Aq13Wkbm7tP2L8kRb_xU-u_YpHwrkWW3nP5g7x-dLnydXEepUJbTqC7mi7wyrajviE-Wuiya-LYyy41PMV0auV7j7C5enJn9lZPNyyEBtc7NqYm0rTTAlVCq6tpE45WtrcOqGlTcu8lJXJWcWMTPCJVpXhVhiRMUOtpynpLuzUTW0_A0mVxZ1QOykcAhPNS8WYo2llqxRrSXgE3zfdXyx7MY0ikOBUFutFgYEqhkBFsNtHZ_QbDYeTaI12XHkpgh0awd4mfMUwHdcFfmd54dRMRvB1tOI88uSIrm1zgy6J8CQUenzqQ71toWe4cVhFICaDYHTwCt1TSz3_G5S6PcmNmCqCH5vhsm3T0y_-5f9d9-BVT22JOEv3Yadd3dgDREhteRimxz1xmA8T
  priority: 102
  providerName: Springer Nature
Title Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array
URI http://dx.doi.org/10.1038/sj.bjc.6605134
https://link.springer.com/article/10.1038/sj.bjc.6605134
https://www.ncbi.nlm.nih.gov/pubmed/19536092
https://www.proquest.com/docview/230009828
https://search.proquest.com/docview/20766578
https://pubmed.ncbi.nlm.nih.gov/PMC2720215
Volume 101
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB2Mwyr66ud0yPQy2Fye2ZVnSY-e2dBsJZayQNyPLUpvQ2iZJR_3f7yR_lGx92ouxuTOydCfp5N_pJ4Q-CRJqFtPcJxAN-7Ew1BciNj4VCTO5MDJ0ZNXTWXJ-GX-f0_kOov1eGJe0r_LFuLy5HZeLa5dbWd-qSZ8nNrmYphY7hKlqsot2wUH7JXrPtBvwlijT_oMTUdAzNRI-WS_H-VKNEwjhQ-JO5LHgZSCirUlpoNR8Xss1NJRpT7h4LAT9N5PyLzjVzVJnL9B-F17i47YaL9GOLl-hp9MOQH-NmjbnzrF9Y0ctizcVXrjduqbBZfVb32Blt7rYPwH4yo6E2O130YXVrO4hbq9t_lyJtWWfkKrBoA6yeyhi02CbSH-FJT6ZHcOLtVyssFytZPMGXZ6d_krP_e70BV_BILjxqSokiQQTOaNSc2KEIblOtGGS6zBPcl6oJC5ixQO4I0WhqGaKRbEi2sKX5ADtlVWp3yEcCg0zpDScGQhYJM1FHBsSFroIoZSAeuhz3_xZ3ZJsZA4cJzxbLzOwWdbZzEMHrXUGvUEw2rLWIIcRmUAQRDx01Jsv67rpOoP1lyVUjbiHPg5S6F8WNJGlru5AJWAWnAKNt62pH76wcx4PsS0nGBQsc_e2BBzaMXh3DuyhL727PHzT4xU__O9CjtCzFgFjfhS-R3ub1Z3-AIHUJh9B95kzuPI0HKEnX09nFz_hKU1SuJ58-zFyHesPwOAkXw
link.rule.ids 230,315,730,783,787,888,12068,12235,21400,27936,27937,31731,31732,33278,33279,33756,33757,41132,42201,43322,43591,43817,51588,53804,53806,74073,74342,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELWgSICEEF-FUGh9QIJL2iR2YvuEqkK1QHdPrdRbZDt2uyuUhE2Kmn_P2PlYLVTcVpqJ4s2Mx09-42eEPggSG0ZTFRJAwyEVNg2FoDZMRcasElbGXqx6vshmF_T7ZXo59OY0Q1vlWBN9oS4q7fbIjwAqO-3LhH-uf4Xu0ihHrg43aNxHD2DVF25e8pNNh4eIeC-Z6XbjRBKNmo2EHzWrQ7XShxmA-ZjQrTVpUtR8UssGvpPtL7i4C4H-20j5F5vqF6nTZ-jpgC7xcZ8Oz9E9U75AD-cDf_4SdX3LnRf7xl5ZFrcVXvrDurbDZfXb_MTanXRxGwH4yhVC7I-7mMJ5VrcA22vXPldi48QnpO4wuIPtFl7Rdtj10V9hib8sjuHBWi7XWK7XsnuFLk6_np_MwuHyhVBDDWzDVBeSJIIJxVJpOLHCEmUyY5nkJlaZ4oXOaEE1j-AXKQqdGqZZQjUxjr0ku2inrErzBuFYGFggpeXMAl6RqRKUWhIXpojhLVEaoI_j58_rXmMj99w44XmzyiFQ-RCoAO320Zn8JsP-VrQmOxRkAhiIBGhvDF8-zNImn3IqQAeTFaaX40xkaaobcImY46bA43Uf6s0IHfENaRUgtpUEk4MT7t62lMtrL-DtuG-AWgH6NKbLZkx3__G3_x3-AXo0O5-f5WffFj_20OOe8GJhEr9DO-36xrwH3NSqfT87_gDRUhii
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7aDYRCKX0lddImOhTai7O2JVvWqaRNlvSRJZQGcjOyLKW7FNtZOyX-9x35tWwbeluYMdZ6RqMPfaNPAG8F9TVnYepSRMMuEyZ0hWDGDUXETSqM9Fux6vN5dHbJvlyFV72kUNW3VQ41sS3UWaHsHvkUobLVvgziqem7Ii5OZh_KG9deIGWJ1v42jYewxVlEvQlsfTydX3xfK_B6cSegaffmROANCo40nlbLo3SpjiKE9j5lGyvUqK_5uJQVfjXTXXdxHx79t63yL261XbJmT-FJjzXJcZccz-CBzp_D9nnPpr-ApmvAa6W_SaszS-qCLNqju6YhefFb_yLKnnux2wLk2pZF0h5-0Zn1LO4QxJe2mS4n2kpRSNUQdEfbHb6ibojtqr8mkpzMj_HBUi5WRK5WsnkJl7PTH5_O3P4qBldhRazdUGWSBoKLlIdSx9QIQ1MdacNlrP00SuNMRSxjKvbwF80yFWqueMAU1ZbLpDswyYtcvwLiC43LpTQxN4heZJgKxgz1M535-BYvdODd8PmTslPcSFqmnMZJtUwwUEkfKAd2uuiMfqPhYCNaox3LM0VERB3YH8KX9HO2SsYMc-BwtOJkswyKzHVxiy4et0wVeux2oV6P0NLgmFYO8I0kGB2sjPemJV_8bOW8LROOwMuB90O6rMd0_x_f--_wD2Ebp0by7fP86z486tgv7gb-a5jUq1v9BkFUnR700-MP23Ueaw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Explorative+study+to+identify+novel+candidate+genes+related+to+oxaliplatin+efficacy+and+toxicity+using+a+DNA+repair+array&rft.jtitle=British+journal+of+cancer&rft.au=Kweekel%2C+D+M&rft.au=Antonini%2C+N+F&rft.au=Nortier%2C+J+W+R&rft.au=Punt%2C+C+J+A&rft.date=2009-07-21&rft.eissn=1532-1827&rft.volume=101&rft.issue=2&rft.spage=357&rft_id=info:doi/10.1038%2Fsj.bjc.6605134&rft_id=info%3Apmid%2F19536092&rft.externalDocID=19536092
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon